• Publications
  • Influence
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
Analysis of the HIV protease gene from the plasma of HIV–infected patients revealed substitutions at nine different codons selected in response to monotherapy with the protease inhibitor ritonavir.Expand
  • 765
  • 31
  • PDF
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
Residual viremia can be detected in most HIV-1-infected patients on antiretroviral therapy despite suppression of plasma RNA to <50 copies per ml, but the source and duration of this viremia isExpand
  • 580
  • 26
  • PDF
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.
Coadministration with the human immunodeficiency virus (HIV) protease inhibitor ritonavir was investigated as a method for enhancing the levels of other peptidomimetic HIV protease inhibitors inExpand
  • 396
  • 20
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
  • D. Kempf, K. Marsh, +7 authors X. Kong
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences…
  • 28 March 1995
Examination of the structural basis for antiviral activity, oral pharmacokinetics, and hepatic metabolism among a series of symmetry-based inhibitors of the human immunodeficiency virus (HIV)Expand
  • 441
  • 15
ART Suppresses Plasma HIV-1 RNA to a Stable Set Point Predicted by Pretherapy Viremia
Current antiretroviral therapy is effective in suppressing but not eliminating HIV-1 infection. Understanding the source of viral persistence is essential for developing strategies to eradicate HIV-1Expand
  • 306
  • 15
  • PDF
Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease
ABSTRACT The association of genotypic changes in human immunodeficiency virus (HIV) protease with reduced in vitro susceptibility to the new protease inhibitor lopinavir (previously ABT-378) wasExpand
  • 235
  • 14
Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children
Background. Lopinavir/ritonavir has demonstrated antiviral activity in the HIV-infected adult. Subjects. The objective of this study was to investigate a liquid coformulation of lopinavir/ritonavir,Expand
  • 135
  • 13
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Study M98-863 was a double-blind, randomized, phase 3 study that compared lopinavir/ritonavir with nelfinavir, each coadministered with stavudine and lamivudine, in 653 antiretroviral therapy-naiveExpand
  • 219
  • 11
ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease
ABSTRACT The valine at position 82 (Val 82) in the active site of the human immunodeficiency virus (HIV) protease mutates in response to therapy with the protease inhibitor ritonavir. By using theExpand
  • 404
  • 10
In Vitro Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants with Increased Resistance to ABT-378, a Novel Protease Inhibitor
ABSTRACT ABT-378, a new human immunodeficiency virus type 1 (HIV-1) protease inhibitor which is significantly more active than ritonavir in cell culture, is currently under investigation for theExpand
  • 172
  • 9
  • PDF